Core Viewpoint - The article highlights the successful IPO of Reebio, a leading small nucleic acid drug company in China, marking a significant milestone in the country's innovative drug sector and the "third wave of drug revolution" [2][3]. Group 1: Company Overview - Reebio officially listed on the capital market at a price of HKD 57.97 per share, closing at HKD 82.1, a 41.6% increase, with a market capitalization of approximately HKD 136.1 billion [2]. - The company is recognized for its unique capabilities, being the only one in Asia with the GalNAc delivery platform, the only Chinese firm to partner with global leader IONIS, and the only local innovator to sign a USD 2 billion collaboration agreement with Boehringer Ingelheim [5]. - Reebio's success is attributed to strong technical barriers and international capabilities, supported by significant investments from notable institutions including Panlin Capital, which has invested across six rounds over ten years [5][11]. Group 2: Industry Context - The small nucleic acid technology was first proposed in 1995, with the first drug entering clinical trials in 2004. The industry faced a downturn after a major drug failure in 2009, but began to recover around 2013-2015 with advancements in delivery technology [7]. - Reebio emerged during the industry's low point, evolving from a pioneer to a leader in the small nucleic acid drug sector over nearly two decades [7][10]. Group 3: Investment Strategy - Panlin Capital's investment journey with Reebio began in 2015, during a challenging fundraising environment for small nucleic acid projects. The firm made its first investment after thorough due diligence, recognizing the potential of small nucleic acid drugs [13][15]. - Over the years, Panlin Capital has consistently supported Reebio through multiple funding rounds, including a critical USD 60 million investment during a downturn in 2019, which was pivotal for the company's growth [16][17]. - The investment philosophy of Panlin Capital emphasizes long-term commitment and value investment, with a focus on supporting projects through various stages of development [23][24].

Core Viewpoint - Ribo Life Science, a leader in the small nucleic acid pharmaceutical field, successfully listed on the Hong Kong Stock Exchange, achieving a market capitalization exceeding HKD 13 billion, representing over 30 times growth compared to its valuation after the A-round investment by Panlin Capital [1][5]. Company Overview - Ribo Life Science was founded in 2007 and is a pioneer in small nucleic acid (siRNA) drug research and development in China, establishing a comprehensive platform for small nucleic acid drug development [7]. - The company focuses on iterative research and development of small nucleic acid chemical modifications and drug delivery technologies, supporting all stages from early research to commercialization [7]. Product Pipeline - Ribo Life Science has developed a robust product pipeline, including: - RBD4059, a siRNA drug targeting FXI for treating thrombotic diseases, which has completed all subject enrollments in Phase IIa clinical trials [8]. - RBD5044, targeting APOC3 for treating hypertriglyceridemia, has received EU approval for Phase II clinical trials [8]. - RBD7022, targeting PCSK9 for treating hypercholesterolemia, has completed Phase I trials in China and is advancing to Phase II trials [8]. - RBD1016, targeting HBV for chronic hepatitis B treatment, is in Phase II trials and has received orphan drug designation from the EMA [10]. Globalization and Commercialization Strategy - Ribo Life Science integrates local R&D advantages with international expertise, establishing a world-class small nucleic acid drug development system [12]. - The company has multiple R&D centers in Suzhou, Beijing, and Europe, and successfully completed a USD 33 million equity financing for its overseas R&D center in Sweden [12]. Strategic Partnerships - In December 2023, Ribo Life Science entered into a licensing and collaboration agreement with Qilu Pharmaceutical for the development and commercialization of RBD7022 in Greater China, receiving over RMB 700 million in upfront and milestone payments [13]. - The company also signed a collaboration agreement with Boehringer Ingelheim to develop innovative therapies for NASH/MASH using its proprietary RiboGalSTAR™ technology, with a total transaction value exceeding USD 2 billion [13]. Investment Journey - Panlin Capital has been a key investor in Ribo Life Science since its A-round financing in 2015, providing crucial support during challenging times in the small nucleic acid industry [5][14]. - The investment journey includes six rounds of funding, demonstrating a commitment to supporting the company's growth and innovation in the biopharmaceutical sector [14][19].